The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction

  title={The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction},
  author={Stephen C. Woods},
  journal={Journal of the American Academy of Physician Assistants},
  • S. Woods
  • Published 1 November 2007
  • Biology, Medicine
  • Journal of the American Academy of Physician Assistants
Although rimonabant has been approved for use in several countries, the Food and Drug Administration has expressed concern about the potential for adverse neurologic and psychiatric effects, considering the widespread distribution of CB1 receptors in the brain. While more research is clearly needed, the clinical evidence shows that CB1-receptor blockade with rimonabant improves multiple cardiovascular and metabolic variables, including body weight and waist circumference, HDL-C, triglycerides… 
Pharmacological tools in endocannabinoid neurobiology.
  • M. Mor, A. Lodola
  • Biology, Chemistry
    Current topics in behavioral neurosciences
  • 2009
This chapter describes the main representatives of several classes of chemicals employed as pharmacological tools in this field, focusing on small organic compounds having, where possible, a drug-like structure.
Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite
A better understanding of how malonyl CoA regulates energy balance should provide novel approaches to targeting intermediary metabolism in the hypothalamus as a mechanism to control appetite and body weight.
Aetiology of addiction
Psychological, social, biological and genetic causes are assumed to play a role in all psychological disorders but only little of this aetiological thinking has led to practical approaches that can
Ätiologie der Abhängigkeitserkrankungen
Bei allen Erkrankungen werden psychologische, soziale, biologische und genetische Ursachen vermutet. Nur wenige dieser atiologischen Uberlegungen fuhren jedoch zu praktisch therapeutisch verwertbaren


Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors, however, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.
It is shown that the lack of CB1 in mice with a disrupted CB1 gene causes hypophagia and leanness, and the cannabinoid system is an essential endogenous regulator of energy homeostasis via central orexigenic as well as peripheral lipogenic mechanisms and might therefore represent a promising target to treat diseases characterized by impaired energy balance.
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
It is concluded that anandamide acting at hepatic CB(1) contributes to diet-induced obesity and that the FAS pathway may be a common molecular target for central appetitive and peripheral metabolic regulation.
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
Results show that SR141716 stimulated Acrp30 mRNA expression in adipose tissue by an effect on adipocytes, and reduced hyperinsulinemia in obese (fa/fa) rats, and suggest a role of metabolic regulation in the antiobesity effect of SR 141716.
Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide
The results show an influence of cannabinoid agents on circulating ghrelin levels and suggest that their short-term action on appetite seems to be in accordance with the control of secretion of gastrointestinal orexigenic peptides, mainly expressed in the upper part of the gastrointestinal tract.
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
It is concluded that SR 141716 has a direct effect on energy expenditure suggesting that the antiobesity effect of SR141716 is due to activation of thermogenesis in addition to the initial hypophagia.